For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Kyowa Kirin Begins PIII for Pegfilgrastim
March 21, 2011
- Pfizer to Enhance Focus on Infectious Diseases
March 21, 2011
- Janssen Begins PIII Trial of Concerta for AD/HD in Adults
March 21, 2011
- Analysts Question Kyowa Kirin's Acquisition of ProStrakan
March 21, 2011
- MediciNova Obtains Patent on Ibudilast to Treat Drug Dependence
March 21, 2011
- Carna Biosciences to Accelerate Licensing of Its Own Compounds
March 21, 2011
- PIII Results for Halaven to Be Published in The Lancet
March 21, 2011
- Citigroup Sees Strong Outlook for Nippon Shinyaku's Vidaza
March 21, 2011
- Pfizer, Daiichi Sankyo Alert Med. Institutions about Use of Prevnar, ActHIB
March 21, 2011
- Januvia Ranked No. 1 in HP, GP Markets: RepTrack Survey
March 21, 2011
- JMA Urges Korosho to Make Quick Decision Regarding ActHIB, Prevnar
March 21, 2011
- Massive Earthquake, Tsunami Hit Northern Japan Paralyzing Business Activities
March 21, 2011
- ActHIB Recalled due to Contamination
March 21, 2011
- Nihon Medi-Physics Provides Radiocesium Decontaminating Agent Free of Charge
March 21, 2011
- Applications Expected for Inactivated Polio Vaccines at End of 2011
March 21, 2011
- R&I to Downgrade Terumo Following Announcement of Acquisition of CaridianBCT
March 21, 2011
- Korosho to Extend HPV Vaccination Period for Girls Currently in 1st Grade of Senior High School
March 21, 2011
- JACDS May Violate Antimonopoly Act by Calling on Members Not to Offer Point Cards
March 21, 2011
- MSD K.K. Submits NDA for Caspofungin
March 21, 2011
- Nichiyakubo to Call For Improvement of Drug Substance Import System
March 21, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…